IL6R and congenital rubella syndrome: As most CAR‐T‐treated patients have elevated serum IL‐6, anti‐IL‐6 (Siltuximab) and anti‐IL‐6R antibody (Tocilizumab) have been used to manage severe CRS (Riegler et al, 2019).